Tag: biomarkers
-
Plasma pTau217 and the actionability gap — diagnostic accuracy for Alzheimer’s has arrived and is regulated, but “does knowing change the outcome” is a separate, still-unproven axis
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All accuracy figures (AUC, concordance, NPV) are attributed to the specific study or assay, and diagnostic accuracy (how well a blood test identifies brain pathology) is kept separate throughout from…
-
CNS antisense oligonucleotides — tofersen missed its clinical primary yet was approved, and eplontersen missed its and was not: same modality, opposite regulatory outcome
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All trial results, reduction figures and safety events are attributed to the sponsoring trial, company or regulator; cross-trial and cross-indication comparisons are not head-to-head. Surrogate-biomarker results (neurofilament light) are kept…
-
A blood test for Alzheimer’s that predicts when, not just whether — and why 0.945 is the wrong number to quote
Evidence-first notes on bioscience, at the edge of the clinic and the market. Information only — not medical or investment advice. The 30-second version What. A new Nature Medicine study (1 July 2026; Phillips et al., corresponding author C. Cruchaga) reports a 34-marker panel of brain-enriched circular RNAs (circRNAs) measured in blood. Its defensible contribution…
Uthando Nethemba 